

BMJ Open Health-related quality of life in Asian patients with breast cancer: a systematic review

Peh Joo Ho,¹ Sofie A M Gernaat,² Mikael Hartman,^{1,3} Helena M Verkooijen^{2,4}

To cite: Ho PJ, Gernaat SAM, Hartman M, *et al.* Health-related quality of life in Asian patients with breast cancer: a systematic review. *BMJ Open* 2018;**8**:e020512. doi:10.1136/bmjopen-2017-020512

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-020512>).

Received 8 November 2017
Revised 11 March 2018
Accepted 15 March 2018



¹Saw Swee Hock School of Public Health, National University of Singapore, Singapore

²Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

³Department of Surgery, National University of Singapore, Singapore

⁴Imaging Division, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Correspondence to

Dr Mikael Hartman;
mikael_hartman@nuhs.edu.sg

ABSTRACT

Objective To summarise the evidence on determinants of health-related quality of life (HRQL) in Asian patients with breast cancer.

Design Systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and registered with PROSPERO (CRD42015032468).

Methods According to the PRISMA guidelines, databases of MEDLINE (PubMed), Embase and PsycINFO were systematically searched using the following terms and synonyms: breast cancer, quality of life and Asia. Articles reporting on HRQL using EORTC-QLQ-C30, EORTC-QLQ-BR23, FACT-G and FACT-B questionnaires in Asian patients with breast cancer were eligible for inclusion. The methodological quality of each article was assessed using the quality assessment scale for cross-sectional studies or the Newcastle-Ottawa Quality Assessment Scale for cohort studies.

Results Fifty-seven articles were selected for this qualitative synthesis, of which 43 (75%) were cross-sectional and 14 (25%) were longitudinal studies. Over 75 different determinants of HRQL were studied with either the EORTC or FACT questionnaires. Patients with comorbidities, treated with chemotherapy, with less social support and with more unmet needs have poorer HRQL. HRQL improves over time. Discordant results in studies were found in the association of age, marital status, household income, type of surgery, radiotherapy and hormone therapy and unmet sexuality needs with poor global health status or overall well-being.

Conclusions In Asia, patients with breast cancer, in particular those with other comorbidities and those treated with chemotherapy, with less social support and with more unmet needs, have poorer HRQL. Appropriate social support and meeting the needs of patients may improve patients' HRQL.

INTRODUCTION

In Asia, the number of breast cancer survivors is increasing, with 5-year survival rates exceeding 90% in early-stage disease.^{1–7} This is due to improved breast cancer treatments and early detection.^{8–11} As such, the number of survivors is increasing rapidly. Patient-reported outcomes on health-related quality of life (HRQL), such as physical and emotional functioning and treatment-related side effects

Strengths and limitations of this study

- This systematic review included over 75 determinants of health-related quality of life in Asian patients with breast cancer.
- Studies included had varying patient selection criteria, which may be the reason for discordance results in certain determinants.
- We were not able to conduct a meta-analysis to provide a sense of the level of association, as the choice of statistical analysis varied across studies.

including pain, nausea and fatigue, are increasingly important as it effects many breast cancer survivors.

Impaired HRQL is best represented as gap between an individual's actual functional level and his or her ideal standard.¹² Studies from the West reported reduced physical and emotional functioning in patients with breast cancer shortly after treatment.^{13–16} Breast-conserving surgery as compared with mastectomy, axillary clearance, radiotherapy and chemotherapy were associated with higher level of pain.¹⁷ Furthermore, younger patients with breast cancer reported better physical functioning but more impaired emotional functioning compared with older breast cancer patients.^{13–16} HRQL improves until up to 6–10 years following breast cancer diagnosis.¹⁸ In Asian population, determinants of HRQL are increasingly being studied.

So far, mainly studies from Western developed countries investigated HRQL following breast cancer.^{14–16 19 20} However, cultural and habitual practices such as the use of traditional medicine may limit the generalisability of results from HRQL studies in Caucasian patients with breast cancer to Asian patients with breast cancer.^{21 22} Drug tolerance is different across populations; paclitaxel in the Japanese population is less well tolerated than the USA.^{23 24} Furthermore, Asian patients with breast cancer tend to be younger at diagnosis and have more advanced stages at diagnosis

Table 1 Search strategy from MEDLINE filters: publication date from 1 January 2000 to 16 February 2016; English

Search strategy (MEDLINE)	
#1	“Breast Neoplasms”[MeSH] OR ((breast[Title/Abstract] OR mamma[Title/Abstract] OR mammary[Title/Abstract]) AND (carcinoma[Title/Abstract] OR carcinomas[Title/Abstract] OR carcinomatosis[Title/Abstract] OR tumor[Title/Abstract] OR tumors[Title/Abstract]) OR tumour[Title/Abstract] OR tumours[Title/Abstract] OR neoplasma[Title/Abstract] OR neoplasms[Title/Abstract]) OR cancer[Title/Abstract] OR cancers[Title/Abstract]))
#2	“quality of life”[MeSH Terms] OR “quality of life”[Title/Abstract] OR hrHRQL[Title/Abstract] OR HRQL[Title/Abstract] OR hrql[Title/Abstract] OR “Functional Assessment of Cancer Therapy”[Title/Abstract] OR “FACT B”[Title/Abstract] OR “FACT-B”[Title/Abstract] OR “FACT G”[Title/Abstract] OR “FACT-G”[Title/Abstract] OR “European Organization for Research and Treatment of Cancer” OR “EORTC QLQ C30”[Title/Abstract] OR “EORTC”[Title/Abstract] OR “EORTC-QLQ-C30” [Title/Abstract] OR “EORTC QLQ BR23”[Title/Abstract] OR “EORTC-QLQ-BR23”[Title/Abstract]
#3	“Asia, Southeastern”[Mesh] OR “India”[Mesh] OR ‘Far East’(Mesh) OR “Southeast asia” OR “South eastern asia” OR “South central” OR China OR Chine* OR Hong Kong OR Hong Kong* OR Macau OR Tibet OR Tibet* OR Japan OR Japan* OR Korea OR Korea* OR Mongolia OR Mongoli* OR Taiwan OR Taiwan* OR India OR India* OR Brunei OR Brunei* OR Indonesia OR Indonesia* OR Lao OR Lao* OR Malaysia OR Malay* OR Myanmar OR Burmese OR Philippin* OR Singapore OR Singapore* OR Thailand OR Thai* OR Timor-Leste OR Timor* OR Vietnam OR Vietnam*
#4	#1 AND #2 AND #3

than Caucasians.²⁵ Even within Asian ethnicities, Malay patients with breast cancer were found to respond better to tamoxifen therapy than Chinese or Indian patients.²⁶ Better understanding of risk factors for poorer HRQL in Asian patients with breast cancer would allow for targeted interventions.

As an overview of the literature on HRQL determinants in Asian breast cancer survivors is currently lacking, this review systematically summarises determinants of HRQL in breast cancer survivors from Eastern, South Central and Southeast Asia.

METHODS

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations and was registered with PROSPERO (CRD42015032468).²⁷

Search strategy

Databases of MEDLINE (PubMed), Embase and PsycINFO were systematically searched, using the terms ‘breast cancer’, ‘quality of life’ and ‘Asia’ in the search strategy (table 1). The systematic search was last updated on 12 July 2017.

Inclusion criteria

Studies were included based on the following criteria: (1) the study population was on women diagnosed with breast cancer living in Eastern Asia, South Central Asia or Southeast Asia; (2) the study was on demographics, clinical, treatments or other determinants of HRQL; (3) the study measured quality of life using European Organization for Research and Treatment of Cancer – Quality of Life Questionnaire, Breast cancer module, EORTC-QLQ-C30, (with or without the breast cancer module, EORTC-QLQ-BR23), or Functional Assessment of Cancer Therapy – General (FACT-G) or Functional Assessment of Cancer Therapy – Breast (FACT-B) questionnaires; (4)

the outcome was HRQL measured quality of life using EORTC-QLQ-C30 (with or without EORTC-QLQ-BR23), or FACT-G or FACT-B questionnaires; and (5) the study design was either cross-sectional or observational longitudinal studies. Studies published before 2000, in language other than English, systematic reviews, meta-analyses, pilot studies and studies with qualitative analyses, were not included in the current review.

Data extraction

After removal of duplicates, all titles and abstracts of the remained retrieved articles were screened. Full-text articles of potentially relevant papers were assessed for eligibility by two authors independently (PJH and SAMG). Disagreement was resolved through consensus. Data extraction was performed by two authors independently (PJH and SAMG). The following determinants were collected for each study: (1) study characteristics (year and country of publication, study design, sample size, response, median follow-up and period), (2) demographics of the study population (age, ethnicity and time since diagnosis), (3) tumour characteristics (invasive or in situ and stage) and (4) past and current treatment.

Outcome extraction included HRQL, as measured by the global health status of the EORTC-QLQ-C30 and overall well-being subscales of FACT-G or FACT-B. The EORTC-QLQ-C30^{28–31} and FACT-G and FACT-B^{32–34} are validated in different populations in different languages. Other domains of the EORTC-QLQ-C30, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, pain, dyspnoea, insomnia, constipation, diarrhoea and financial difficulty were extracted where available. The EORTC-QLQ-BR23, an additional breast cancer module, assesses areas that are specific to patients with breast cancer: body image, sexual functioning, sexual enjoyment, future perspectives, systemic therapy side effects, breast symptoms and arm symptoms. Similarly,




Figure 1 Flow diagram of study selection. HRQL, health-related quality of life.

determinants of other domains of FACT-G, physical well-being, social well-being, emotional well-being and functional well-being were extracted. The FACT-B, an extended version of the FACT-G, has an additional breast cancer subscale.

Quality assessment

Critical appraisal was performed using the quality assessment scale for cross-sectional studies,³⁵ and an adapted version of Newcastle-Ottawa Quality Assessment Scale for cohort studies.³⁶ The maximum score attainable was 8 for each cross-sectional study and 6 for each longitudinal study. Four items on sample selection, one on comparability and three on outcome measurement, were assessed for cross-sectional studies (online supplementary table 1). Two items on sample selection, one on comparability (score of 0–2) and two on outcome measurement, were assessed for cohort studies (online supplementary table 2). Meeting all criteria in the category would confer a high score in the category. Except for the comparability criterion of cross-sectional study, studies that meet <50% of the criteria would be considered as having a low score.

Patient and public involvement

Patients and public were not involved in the development of the research question, choice of outcome measures or the design and conduct of this systematic review.

RESULTS

The systematic search yielded a total of 3160 records including 2549 unique articles that were screened for title and abstract using the predefined inclusion and exclusion criteria (figure 1). After screening the full text of 182 articles, 126 articles did not meet our inclusion and exclusion criteria (figure 1). Cross-referencing identified one additional article. In total, 57 articles were included in the systematic review (43 cross-sectional studies and 14 longitudinal studies), including 24538 women diagnosed with breast cancer from the following seven countries: Korea (n=17), China (n=14), India (n=8), Taiwan (n=6), Malaysia (n=6), Japan (n=5) and Thailand (n=1) (table 2).

Table 2 Description of identified studies

Author, year	Study design	Questionnaire	Ethnicity	Sample size (response rate, %)	Period of recruitment	Time of questionnaire assessment	Age, mean (SD)	Tumour stage	Quality assessments (max 6 or 8) ^a
Noh <i>et al.</i> , 2008 ²²	Cross-sectional	C30	Japanese	2085 (26)	2004	4.2 (1.3–11.9) years since surgery*	57.8% were aged ≥50 years	In situ, I–IV	7
Akechi <i>et al.</i> , 2010 ⁷⁰	Cross-sectional	C30	Japanese	408 (97)	2006–2007	2.8 (3.7) years since diagnosis	56.1 (12.1)	In situ, I–IV	6
Edib <i>et al.</i> , 2016 ⁴⁸	Cross-sectional	C30	Malay, Chinese and Indian	117 (80)	2014	42.7% were 1–2 years, 42.7% were aged <40 years, 24.8% were aged 40–49, 2–5 years, 14.6% were >5 years since diagnosis	13.7% were aged <40 years, 24.8% were aged 40–49, 61.6% were aged ≥50 years	In situ, I–IV	6
Kim <i>et al.</i> , 2012 ⁵¹	Cross-sectional	C30 ⁴	Korean	136 (83)	2010–2011	2.6 (2.1) years since diagnosis	50 (7.8)	In situ, I–III	6
Huang <i>et al.</i> , 2017 ⁵⁰	Cross-sectional	C30	Chinese	252	–	5.6 (2.6) years since diagnosis	54.5 (8.3) age at time survey	I–IV	4
Liang <i>et al.</i> , 2016 ⁵⁴	Cross-sectional	C30 ³	Chinese	201	–	4.2 (5.4) years since diagnosis	53.6 (9.5)	In situ, I–IV	3
Jang <i>et al.</i> , 2013 ⁸²	Longitudinal	C30 ³	Koreans	284 (81)	2008–2009	Within 5 days of surgery	49.8 (9.5)	In situ, I–IV	5
Wani <i>et al.</i> , 2012 ³⁹	Longitudinal	C30	Indian	81	–	During chemotherapy or radiotherapy	46.6 (10.2)	–	3
Yusuf <i>et al.</i> , 2013 ⁵³	Cross-sectional	C30+BR23	Chinese, Malay (Malaysia)	79 (96)	2010–2011	Newly diagnosed before the start of treatment	Malay: 50.7 (95% CI 48.1 to 53.3) Chinese: 50.2 (95% CI 43.8 to 56.8)	I–IV	6
Kim <i>et al.</i> , 2015 ⁶¹	Cross-sectional	C30+BR23	Korean	531 (61)	–	–	BCS: 48.4 (8.7), TM: 49.3 (7.5), TM-R: 43.5 (9.2)	In situ, I–III	6
Chui <i>et al.</i> , 2015 ²¹	Cross-sectional	C30+BR23	Chinese, Malay, Indian, other (Malaysia)	546 (89)	2012–2013	On chemotherapy	–	In situ, I–IV	6
Lee <i>et al.</i> , 2007 ⁶⁷	Cross-sectional	C30+BR23	Korean	152	–	1.8 (0.5–1.0) years since recurrence*	65.8% were aged <50 years	I–III	6
Sun <i>et al.</i> , 2014 ⁸²	Cross-sectional	C30+BR23	Korean	407 (80)	2011–2012	BCS: 4 (1.6), TM: 4.1 (1.8), TM-R: 4.7 (1.9)	BCS: 52.3 (8.5), TM: 51.9 (8.9), TM-R: 45.2 (7.5)	In situ, I–III	6
Okamura <i>et al.</i> , 2005 ⁹³	Cross-sectional	C30+BR23	Japanese	59 (85)	2001–2002	–	53 (10)	All patients at first recurrence, with 98% stage IV	5
Huang <i>et al.</i> , 2010 ⁶⁰	Cross-sectional	C30+BR23	Chinese (Taiwan)	130 (100)	2004–2007	Completed surgery or final course of chemotherapy for at least 9 months	BCS: 51.1 (22–78) TM: 55.1 (32–77) ^h	In situ, I–III	5

Continued

Table 2 Continued

Author, year	Study design	Questionnaire	Ethnicity	Sample size (response rate, %)	Period of recruitment	Time of questionnaire assessment	Age, mean (SD)	Tumour stage	Quality assessments (max 6 or 8) ^a
Kang <i>et al.</i> , 2012 ²²	Cross-sectional	C30+BR23	Korean	399 (60)	2008–2009	CAM users: 2.7 (2.2), Non-CAM users: 2 (1.6) years since diagnosis	CAM users: 50.6 (9.4), non-CAM users: 50.6 (11.1)	In situ, I–IV	5
Park <i>et al.</i> , 2012 ³⁸	Cross-sectional	C30+BR23	Korean	59 (30)	2007–2010	–	56.31 (94.5)	I–IV	5
Tang <i>et al.</i> , 2016 ⁷³	Cross-sectional	C30+BR23	Chinese	6188	–	–	56.9 (9.0)	In situ, I–IV	5
Kang <i>et al.</i> , 2017 ⁹⁴	Cross-sectional	C30+BR23	Korean	283 (81)	–	At least 1 year since diagnosis	48.5 (7.8) age at time of survey	In situ, I–III	5
Dubashi <i>et al.</i> , 2010 ⁵⁹	Cross-sectional	C30+BR23	Indian	51 (51)	–	5 (2–11) years since diagnosis ⁱⁱ	35	I–III	4
Shin <i>et al.</i> , 2017 ⁹⁵	Cross-sectional	C30+BR23	Korean	231	2012–2015	13.4% were 0.5–1 year, 74.5% 1–5 years, 11.7% ≥5 years since surgery	48.1 (8.4)	I–III	4
Chang <i>et al.</i> , 2014 ⁴⁹	Cross-sectional	C30+BR23	Korean	126	2009	–	47.7 (8.1)	I–III	3
Sharma and Purkayastha, 2017 ⁹⁶	Cross-sectional	C30+BR23	Indian	60	2014–2016	On radiotherapy	Mean 47.6 (range 30–75)	I–III	2
Kao <i>et al.</i> , 2015 ⁴⁶	Longitudinal	C30+BR23	Chinese (Taiwan)	408 (81)	2010–2012	Before surgery	52.2 (9.6)	In situ, I–IV	6
Munshi <i>et al.</i> , 2010 ³⁸	Longitudinal	C30+BR23	Indian	255 (76)	–	During radiotherapy	–	In situ, I–III	5
Lee <i>et al.</i> , 2011 ⁷⁸	Longitudinal	C30+BR23	Korean	299 (81)	2004–2006	Within days/weeks of diagnosis	46.6 (10)	I–IV	5
Shi <i>et al.</i> , 2011 ⁴⁷	Longitudinal	C30+BR23	Chinese	132 (77)	2007–2008	Before surgery	BCS: 50.3 (8.6), TM: 53.84 (10.2), TM-R: 47.7 (8.2)	In situ, I–III	5
Ng <i>et al.</i> , 2015 ⁴¹	Longitudinal	C30+BR23 ³	Chinese, Malay, Indian, other (Malaysia)	221	2011–2015	Newly diagnosed	55.1 (11.5)	In situ, I–IV	4
Munshi <i>et al.</i> , 2012 ⁹⁷	Longitudinal	C30+BR23	Indian	188	–	During radiotherapy	–	In situ, I–III	3
Damodar <i>et al.</i> , 2013 ³⁷	Longitudinal	C30+BR23	Indian	41	2011	During chemotherapy	46.1 (11.2)	–	3
Sultan <i>et al.</i> , 2017 ⁴⁰	Longitudinal	C30+BR23	Indian	25 (76)	2014–2015	Newly diagnosed	Mean 40 (range: 28–65)	I	3
So <i>et al.</i> , 2014 ⁵¹	Cross-sectional	FACT-G	Chinese	163	2010–2011	1.2 (0.9–1.6) years since diagnosis*	51 (9.2)	In situ, I–IV	3
Wong and Fielding, 2007 ⁹⁸	Longitudinal	FACT-G	Chinese	249 (86)	–	–	48.4 (11.9)	In situ, I–IV	5
Yan <i>et al.</i> , 2016 ⁵³	Cross-sectional	FACT-B	Chinese	1160 (64)	2013	15.0 (6.7) years since diagnosis	57.7 (11.5)	In situ, I–IV	7
Ohsumi <i>et al.</i> , 2009 ⁴⁴	Cross-sectional	FACT-B	Japanese	93 (93)	2004–2005	7 (5–11) years since surgery ⁱⁱ	58 (44–83) age at time of survey ⁱⁱ	–	6

Continued

Table 2 Continued

Author, year	Study design	Questionnaire	Ethnicity	Sample size (response rate, %)	Period of recruitment	Time of questionnaire assessment	Age, mean (SD)	Tumour stage	Quality assessments (max 6 or 8) [^]
Park <i>et al.</i> , 2011 ⁴²	Cross-sectional	FACT-B	Korean	1094 (88)	–	73.4% were ≤3 years since surgery	46.9 (8.8)	I–III	5
Park and Hwang, 2012 ⁷¹	Cross-sectional	FACT-B	Korean	52 (94)	2007–2008	1.7 (1.8) years since recurrence	48.3 (8.3) age at recurrence	–	5
Thanarpan <i>et al.</i> , 2015 ⁹⁶	Cross-sectional	FACT-B	Thai	127	2014–2014	–	51.9 (8.9)	In situ, I–III	5
He <i>et al.</i> , 2012 ⁶³	Cross-sectional	FACT-B	Chinese	180 (90)	2000–2008	BCT: 5 (1.3–8.5), TM: 5.4 (1.3–9.6) years since diagnosis*	BCS: 44 (10), TM: 45 (9)	I–II	4
Hong-Li <i>et al.</i> , 2014 ⁵⁵	Cross-sectional	FACT-B	Chinese	154	2008–2010	Group 1: 1 year (n=64), group 2: 2 years (n=48), group 3: 5 years since diagnosis (n=42)	Group 1: 47.4 (8.8), group 2: 43.3 (10.3), group 3: 59.1 (9.4)	I–III	4
Chang <i>et al.</i> , 2007 ⁹⁹	Cross-sectional	FACT-B	Chinese (Taiwan)	235 (94)	–	3 (1–12) years since diagnosis*	49 (32–69)	I–IV	4
Kim <i>et al.</i> , 2013 ¹⁰⁰	Cross-sectional	FACT-B	Korean	77	–	–	49.2 (7.7)	I–IV	4
So <i>et al.</i> , 2013 ^{101†}	Cross-sectional	FACT-B	Chinese	279 (80)	2007	–	–	In situ, I–IV	4
Zou <i>et al.</i> , 2014 ⁷⁵	Cross-sectional	FACT-B	Chinese	156 (87)	–	–	47.7 (10.3)	–	4
Jiao-Mei <i>et al.</i> , 2015 ⁷⁴	Cross-sectional	FACT-B	Chinese	93	2013–2013	5.6 (1.8) years since diagnosis	51.76 (88.9)	I–IV	4
Qiu <i>et al.</i> , 2016 ¹⁰²	Cross-sectional	FACT-B	Chinese	76 (76)	2014	52.97 months since diagnosis	Mean 45.8 (range 23–76) age at time of survey	–	4
Shin and Park, 2017 ⁵⁷	Cross-sectional	FACT-B	Korean	264 (94)	2014	56.1% were ≤1 year, 32.6% 1–5 years, 11.4% ≥5 years since diagnosis	4.2% were aged ≤39 years at time of survey, 29.9% 40–49, 53.8% 50%–59, 12.1% ≥60	?–III	4
So <i>et al.</i> , 2011 ^{45, †}	Cross-sectional	FACT-B	Chinese	261	2006–2007	During chemotherapy or radiotherapy	21% were aged ≥60	In situ, I–IV	3
Park and Yoon, 2013 ^{59, §}	Cross-sectional	FACT-B	Korean	200	–	During chemotherapy	45.6 (7.1)	I–IV	3
Pahlevan Sharif, 2017 ^{76¶}	Cross-sectional	FACT-B	Chinese, Malay, Indian, other	118 (93)	2016	2.9 (1.9) years since diagnosis	51.0 (9.4)	I–III	3
Sharif and Khaneikharab, 2017 ^{77¶}	Cross-sectional	FACT-B	Chinese, Malay, Indian, other	130	–	3.0 (1.9) years since diagnosis	51.2 (9.3)	I–III	2
So <i>et al.</i> , 2009 ^{103†, **}	Cross-sectional	FACT-B	Chinese	215 (75)	–	5.5 (3) years since diagnosis	51.65 (10.4)	I–IV	4
Pandey <i>et al.</i> , 2005 ^{104, ††}	Cross-sectional	FACT-B	Indian	504 (99)	–	–	47.6 (11)	I–IV	3

Continued

Table 2 Continued

Author, year	Study design	Questionnaire	Ethnicity	Sample size (response rate, %)	Period of recruitment	Time of questionnaire assessment	Age, mean (SD)	Tumour stage	Quality assessments (max 6 or 8) [^]
Cao <i>et al.</i> , 2016 ⁶⁵	Longitudinal	FACT-B	Chinese	486 (92)	2010–2013	Start hormone therapy	57.3 (range: 27–79)	–	6
Pandey <i>et al.</i> , 2006 ⁶⁸	Longitudinal	FACT-B	Indian	254 (99)	2002–2003	Presurgery and postsurgery time points were used	45.6 (10.6)	7–IV	5
Taira <i>et al.</i> , 2012 ⁶⁴	Longitudinal	FACT-B	Japanese	140	1998–2003	Less than 6 weeks since surgery	53 (24–77)	In situ, I–III	5
Gong <i>et al.</i> , 2017 ⁶⁹	Cross-sectional	C30+FACTG	Chinese	3344 (65)	2013	8.5 (6.5) years since diagnosis	59.3 (7.9) age at time of survey	–	5

[^]Median (IQR).

[†]Same sample population.

[‡]Same sample population.

[§]Max score of 6 for longitudinal studies, while 8 for cross-sectional studies.


[¶]Same sample population.

^{**}Significance of associations not reported.

^{††}Direction of association not reported.


BR23, EORTC-QLQ-BR23; BCS, breast-conserving surgery; C30, EORTC-QLQ-C30; TM, mastectomy; TM-R, mastectomy with reconstruction.

A Cross-sectional studies



Selection: Low [Score: 0-1], Moderate [2-3], High [4]
 Comparability: Low [0], High [1]
 Outcome: Low [0-1], Moderate [2], High [3]

B Cohort studies



Selection / Comparability / Outcome: Low [0], Moderate [1], High [2]

Figure 2 Quality assessment using the quality assessment scale for cross-sectional studies or an adapted version of Newcastle–Ottawa Quality Assessment Scale for cohort studies. Selection was based on the representativeness of the study population or cohort. Comparability and outcome were based on method of determining and reporting exposure of interest and outcome, respectively.

Quality assessment

Of the 43 studies with a cross-sectional design, none received the maximum score of the quality assessment (table 2). There were 22 articles with a low score for selection (score of 0–2) due to the use of convenience sampling and small (<300) sample size (online supplementary table 1). All cross-sectional studies described their study population, conferring a high score for comparability (figure 2). Reporting of outcome was an issue in cross-sectional studies: 20 studies did not report confidence intervals or standard errors and 27 had <70% response rate (online supplementary table 1). Nine of 14 longitudinal studies were of good quality having scores of 5–6 (max=6) (table 2). The remaining five studies of poorer quality with scores of 3 or 4, four did not have a representative sample of their target population,^{37–40} four had a follow-up of <70% but did not provide description of lost to follow-up and none controlled for additional determinants^{37–41} (online supplementary table 2).

Most determinants studied were consistent in the direction of association or were not associated with global health status and/or general well-being (table 3). In studies on global health status, marital status, household income, type of surgery, chemotherapy, radiotherapy and hormone therapy, conflicting results were found. Studies on general well-being, looking at time since diagnosis, age and unmet sexuality needs measured by short-form

Table 3 Associations studied using EORTC-QLQ-C30/EORTC-QLQ-BR23 or FACT-G/FACT-B

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Studies using the EORTC-QLQ-C30 questionnaire			
Cross-sectional (n=5)			
Noh, 2008 ^{72*}	Global health status and social functioning Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning Global health status, physical functioning, role functioning and social functioning Global health status, role functioning, emotional functioning, cognitive functioning and social functioning	Involved in decision making Reflection of own value to decision Experience of treatment toxicity Hospitalisation with treatment toxicity Problem obtaining surgery Having regular follow-up	Positive Negative Negative Negative
Akechi, 2010 ^{70†}	Global health status	Higher scores in the domains of SCNS: psychological, physical and daily living, sexuality, health system and information, care and support	– Negative
Studies using the EORTC-QLQ-BR23 or FACT-G/FACT-B			
Edeb, 2016 ^{68†}	Global health status	Time since diagnosis (<2, 2–5 and >5 years) Ethnicity (Malay vs Chinese vs Indian) Higher household income (<RM2000, RM2000–RM4000 and >RM4000) Breast-conserving surgery versus mastectomy Immune therapy (yes vs no) Unmarried (Un) versus married (M) versus widowed/divorced (WD) Older age (≤40, 40–49 and ≥50) Employed versus retired versus housewife Higher stage (0, 1, 2, 3 and 4) Radiotherapy (yes vs no) Chemotherapy (yes vs no) Hormone therapy (yes vs no) Higher scores in SCNS – physical needs Higher scores in SCNS – psychological needs Higher scores in SCNS – care and support needs SCNS – sexuality needs SCNS – health system and information needs Higher bone density	Positive – W/D<M < Un Negative – – Positive Positive
Kim, 2012 ^{61*}	Role functioning	–	–
Huang, 2017 ^{69†}	Global health status	Time since diagnosis (2–3, 3–5 and ≥5 years) Higher household income (≤US\$1000, US\$1001–US\$2000 and ≥US\$2001) Tumour stage Comorbidities (0, 1, 2 and ≥3) Treatment (combinations of surgery (S), chemotherapy (C), radiotherapy (R), hormone therapy (H), targeted therapy (T)) Illness duration (ref: 2–3, 3–5 and ≥5 years) Recurrence or metastasisation	Positive – – Negative C>S+C+H>S+C+R+H+T+S+C>others>S+R+ hour>S+C+R+hour>S+C+R>SH 3–5 years>2–3 years –

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Liang, 2016 ⁵⁴ †	Global health status	Year of diagnosis	Negative
	Global health status	Symptom distress	
		Symptom management self-efficacy	Positive
Longitudinal (n=2)			
Jang, 2012 ⁵⁴ †	-	Presence of religion	-
	-	Higher religious activity (at 5 days and 1 year postsurgery)	-
	-	Higher intrinsic religiosity at 5 days postsurgery	-
	Global health status	Higher intrinsic religiosity at 1 year postsurgery	Positive
Wani, 2012 ³⁹	Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning	Time at first chemotherapy treatment, 6, 12 and 24 months after first visit	Positive
	Fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulty		Negative
Studies using the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaire			
Cross-sectional (n=13)			
Yusuf <i>et al</i> 2013 ⁵³	Nausea and vomiting, dyspnoea, constipation and breast symptoms	Malay versus Chinese	Positive
Kim <i>et al</i> , 2015 ⁶¹	Role functioning, social functioning, body image and fatigue	Breast-conserving surgery versus mastectomy	Positive
	Pain, insomnia and arm symptoms		Negative
	Body image and fatigue	Breast-conserving surgery versus mastectomy with reconstruction	Positive
	Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective	Better subjectively measured cosmesis	Positive
	Fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea, systemic therapy side effects, breast symptoms, arm symptoms and hair loss		Negative
	Body image	Objectively measured cosmesis (good vs poor)	Positive
	Body image and diarrhoea	Panel score for cosmesis (good vs poor)	Positive

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Chui et al, 2015 ²¹	<ul style="list-style-type: none"> - Global health status 	<ul style="list-style-type: none"> Age (30–39, 40–49, 50–59 and ≥60)‡ Ethnicity (Malay vs Indian)‡ Ethnicity (Chinese vs Indian)‡ Education (tertiary vs primary/lower)‡ Education (secondary vs primary/lower)‡ Household income (≤RM3000 vs >RM3000)‡ Single versus ever married‡ Chemotherapy (postponed vs on schedule)‡ Stage (early vs late)‡ Chemotherapy cycles (2/3/4 vs 5/6)‡ Complementary and complementary medicine (MBP vs MBP-NP vs MBP-NP-TMed)‡ Complementary and complementary medicine (users vs non-users) Complementary and complementary medicine (single (S), dual (D), triple (T) modality) 	<ul style="list-style-type: none"> - Positive
Lee, 2007 ⁶⁷ §	<ul style="list-style-type: none"> - Financial difficulty, sexual enjoyment, systemic therapy side effects and breast symptoms - Emotional functioning and cognitive functioning - Body image and future perspective - Upset by hair loss - Systemic therapy side effects - Global health status 	<ul style="list-style-type: none"> Presence of religion Presence of one or more comorbidity Incomplete versus completed treatment Problems before surgery Involved in decision making Better perceived overall medical care Time since diagnosis (≥5 years vs <5 years) Treatment status: post. versus ongoing versus non 	<ul style="list-style-type: none"> Positive Positive - Post > (Ongoing = Non) Negative
Sun, 2014 ⁶²	<ul style="list-style-type: none"> - Emotional functioning, social functioning and body image - Nausea and vomiting, financial difficulty, arm symptoms (score for mastectomy with reconstruction was lower than for those with breast-conserving surgery) 	<ul style="list-style-type: none"> Breast-conserving surgery versus mastectomy with reconstruction 	<ul style="list-style-type: none"> Positive Negative
Okamura, 2005 ⁶³	<ul style="list-style-type: none"> - Emotional functioning, body image and future perspective - Fatigue, nausea and vomiting, appetite loss and diarrhoea 	<ul style="list-style-type: none"> Presence of psychiatric disorder 	<ul style="list-style-type: none"> Negative Positive

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Huang, 2010 ⁶⁰	Dyspnoea	Older age	Positive
	Role functioning	Married (yes vs no)	Negative
	Breast symptoms		Positive
	Global health status and role functioning	Breast-conserving surgery versus mastectomy	Negative
	Fatigue, pain, dyspnoea, insomnia, appetite loss, breast symptoms and arm symptoms		Positive
	Insomnia, breast symptoms and arm symptoms	Adjuvant therapy (yes vs no)	Positive
	Insomnia	Hormone therapy (yes vs no)	Positive
	Arm symptoms	Use of complementary and complementary medicine	Positive
	Sexual functioning and sexual enjoyment	Older age	Negative
	-	Tumour size	-
Kang, 2012 ²²	-	Lymph nodes involvement	-
	Global health status	Metastatic disease	Negative
	Physical functioning and role functioning		Positive
	-	Postsurgery versus presurgery	-
	-	Axillary clearance	-
	Pain	Chemotherapy (yes vs no)	Negative
	Appetite loss, sexual enjoyment	Radiotherapy (yes vs no)	Negative
	Future perspective	Hormone therapy (yes vs no)	Positive
	-	Self-massage	-
	-	Lymphoedema duration	-
Tang, 2016 ⁷³	Global health status, physical functioning, role functioning, emotional functioning, body image and future perspective	Diabetes mellitus (yes vs no)	Negative
	Fatigue, nausea and vomiting, pain, dyspnoea, insomnia, constipation, diarrhoea, financial difficulty, systematic therapy side effects, breast symptoms, arm symptoms and upset with hair loss		Positive
	Global health status, cognitive functioning, emotional functioning and constipation	Type 1 diabetes mellitus versus no diabetes mellitus	Negative
	Fatigue, nausea and vomiting, dyspnoea, insomnia, diarrhoea, systematic therapy side effects and breast symptoms		Positive
	Global health status, physical functioning, role functioning, sexual functioning, sexual enjoyment, future perspective, fatigue and constipation	Type 2 diabetes mellitus versus no diabetes mellitus	Negative
	Body image, pain, dyspnoea, insomnia, appetite loss, financial difficulty, systematic therapy side effects, breast symptoms, arm symptoms and upset with hair loss		Positive
	Global health status, physical functioning, cognitive functioning, emotional functioning, role functioning, body image and future perspective	Happiness status (Subjective Happiness Scale)	Positive
	Fatigue, nausea and vomiting, pain, insomnia, appetite loss, constipation, financial difficulties, systemic therapy side effects, arm symptoms and upset with hair loss		Negative
	-		-
	-		-

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Dubashi, 2010 ⁵⁹	Global health status, sexual functioning and sexual enjoyment Arm symptoms	Breast-conserving surgery versus mastectomy	Negative Positive
Shin, 2017 ⁶⁵	Sexual functioning and sexual enjoyment Fatigue and pain Sexual functioning Physical functioning (only among stage I)	Having had ovarian ablation Higher levels of physical activity (metabolic equivalent-hours per week) (tertiles)	Negative Negative Positive Positive
Chang, 2014 ⁶⁴	Global health status Body image - - Body image -	Education (more than high school vs less than middle school) Married versus single/divorced/separated/widowed Household income (>\$3000 vs <\$3000) Employed versus unemployed Stage (1, 2, 3 and unknown) Being on active treatment Breast-conserving surgery versus mastectomy Time of radiotherapy (every day for 5 days)	Positive Positive Negative - - Positive -
Sharma, 2017 ⁶⁶	-	-	-
Longitudinal (n=7)	-	-	-
Kao, 2015 ^{66**}	Global health status, emotional functioning, body image, sexual functioning, sexual enjoyment and future perspective Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, body image, sexual functioning, sexual enjoyment and future perspective Cognitive functioning and body image Role functioning, emotional functioning, cognitive functioning and body image Physical functioning, emotional functioning, body image, sexual functioning and sexual enjoyment Global health status, physical functioning, emotional functioning, body image and future perspective Global health status, emotional functioning, body image and future perspective Global health status, body image and future perspective Physical functioning, role functioning, emotional functioning, cognitive functioning, body image, sexual functioning and sexual enjoyment	Older age (years) Longer time since diagnosis (at 6 months/1 year/2 years vs at time of diagnosis) Charlson comorbidity index Tumour stage (3/4 vs 0/1) Tumour stage (2 vs 0/1) Breast-conserving surgery versus mastectomy Breast-conserving surgery versus mastectomy with reconstruction Chemotherapy (yes vs no) Radiotherapy (yes vs no) Hormone therapy (yes vs no) Longer postoperative length of stay	Negative Positive Negative Negative Negative Positive Positive Negative Negative Positive Positive Negative Positive Positive Negative
Munshi, 2010 ⁶⁸	Social functioning and arm symptom	Breast-conserving surgery versus mastectomy prior to radiotherapy	Negative
Lee, 2011 ⁷⁸	Sexual enjoyment and future perspective Diarrhoea	Longer time since diagnosis (1 year postdiagnosis vs at diagnosis)	Positive Negative

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Shi, 2011 ⁴⁷	Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective Role functioning, emotional functioning, cognitive functioning and body image Physical functioning, emotional functioning, sexual functioning and sexual enjoyment Body image Global health status Body image, sexual functioning and sexual enjoyment Global health status, physical functioning, emotional functioning, body image and future perspective Global health status, emotional functioning, body image and future perspective Global health status and body image Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective	Longer time since diagnosis (2 vs 1 year) Breast-conserving surgery versus mastectomy Breast-conserving surgery versus mastectomy with reconstruction Older age Chemotherapy (yes vs no) Radiotherapy (yes vs no) Hormone therapy (yes vs no) Preoperative quality of life score	Positive Positive Negative Positive Negative Positive Positive Positive Positive Positive
Ng, 2015 ^{41,††}	Emotional functioning Physical functioning Global health status, emotional functioning and social functioning	At 6 months postdiagnosis versus at time of diagnosis At 12 months postdiagnosis versus at time of diagnosis	Positive Negative Positive
Munshi, 2012 ³⁷	–	Radiotherapy using cobalt machine versus linear accelerator at completion of radiotherapy	–
Damodar, 2013 ³⁷	Physical functioning, role functioning and future perspective Fatigue, insomnia, arm symptoms and upset with hair loss	At ≥ 5 versus ≤ 2 cycles of chemotherapy	Negative Positive
Sultan, 2017 ⁴⁰	Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, sexual functioning, arm symptoms and breast symptoms Fatigue, pain, dyspnoea, appetite loss, diarrhoea, sexual enjoyment and upset with hair loss	Chemotherapy (cycle ref: 1, 3, 6)	Negative Positive
Studies using the FACT-G questionnaire Cross-sectional (n=1)			

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
So, 2014 ^{51†}	-	Age (years)	-
	-	Time since diagnosis (months)	-
	-	Comorbidity (yes vs no)	-
	-	Education (no formal/primary vs secondary or higher)	-
	-	Employed versus unemployed/retired/homemaker	-
	-	Household income (≤HK\$10 000, HK\$10 001–HK\$30000 and >HK\$30 000)	-
	-	Married/cohabitation versus single/divorced/widowed	-
	-	Living alone (yes vs no)	-
	-	Family history (yes vs no)	-
	-	Stage (≤2 vs ≥3)	-
	-	Cancer is under control versus progression (yes vs no/unsure)	-
	-	Number of treatment received (one vs ≥2)	-
	-	Hormone therapy (yes vs no)	Positive
	-	Longer time needed to travel from home to hospital (minutes)	Negative
	-	Higher scores in the domains of SCNS – psychological, physical and daily living, sexuality, health system and information, care and support	
Longitudinal (n=1)			
Wong, 2007 ^{56,††}	Overall well-being, physical well-being and functional well-being	Longer time since diagnosis	Positive
	Overall well-being and physical well-being	Positive mood	Positive
	Overall well-being and functional well-being	Higher levels of boredom	Negative
Studies using the FACT-B questionnaire			
Cross-sectional (n=15)			

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Yan, 2016 ⁴³	Overall well-being, social well-being and functional well-being	Age (<44, 45–54, 55–64 and ≥65 years)	Negative
	Breast cancer subscale		Positive
	Overall well-being, social well-being, emotional well-being and functional well-being	Primary school or less (L) versus middle/high school (M) versus college or more (C)	L<M<C
	Physical well-being		M<L<C
	Social well-being	Married (Ma) versus single (S) versus widowed (W) versus divorced (D)	D<S<W<Ma
	Breast cancer subscale		Ma<D<W<S
	Overall well-being, physical well-being, emotional well-being and functional well-being	Working in the public sector (G) versus private sector (P) versus farmers/unemployed (U)	U<P<G
	Social well-being		P<U<G
	Breast cancer subscale		U<G<P
	Overall well-being, social well-being, emotional well-being and functional well-being	Household income (<1000, 1001–3000, 3001–5000, >5000RMB)	Positive
	Physical well-being		Generally positive
	Overall well-being, physical well-being, functional well-being and breast cancer subscale	URBMI/NRCMS (UR) versus UEBMI health insurance (UE) versus undefined (Un)	UR<Un<UE
	Emotional well-being		UR<UE<Un
	–	Stage (0/1, 2, 3, 4, unknown)	–
	–	Breast-conserving surgery versus mastectomy	–
	Overall well-being, physical well-being, emotional well-being and breast cancer subscale	Chemotherapy (yes vs no)	Negative
	Overall well-being, physical well-being, social well-being, emotional well-being, functional well-being and breast cancer subscale	Traditional Chinese medication (yes vs no)	Positive
	Overall well-being, emotional well-being and breast cancer subscale	Time since diagnosis (<11.9 (A), 12–23.9 (B), ≥24 (C) months)	A<C<B
	Physical well-being, social well-being and functional well-being	Family harmony status (good vs not so good)	A<B<C
	Overall well-being, physical well-being, social well-being, emotional well-being, functional well-being and breast cancer subscale	Interaction with friends/neighbours (never, sometimes and frequent)	Positive
	Overall well-being, social well-being, emotional well-being and functional well-being	Participation in healing club (yes vs no)	Positive
	Breast cancer subscale		Negative
	Overall well-being, social well-being, emotional well-being and functional well-being	Participation in peer-patient activities and communication	Positive
	Overall well-being, physical well-being, social well-being, emotional well-being and functional well-being	Score on Perceived Social Support Scale (<50, 50–69 and ≥70)	Positive

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes	
Ohsumi, 2009 ⁴⁴	Overall well-being and social well-being	Older age (>60 vs ≤60 years)	Negative	
	-	Time since surgery (≥85 vs <85 months)	-	
	Social well-being	Education (≥10 vs <10 years)	Positive	
	-	Employed versus unemployed	-	
	-	Household income (>10, 5–10 and ≤5 million yen)	-	
	-	Married versus others	-	
	-	Comorbidity (yes vs no)	-	
	-	Lymph node status	-	
	Breast cancer subscale	Breast-conserving surgery versus mastectomy	Positive	
	-	Chemotherapy (yes vs no)	-	
	-	Hormone therapy (yes vs no)	-	
	Park, 2011 ⁴²	Overall well-being, physical well-being, social well-being, functional well-being and breast cancer subscale	Older age (≥50 vs <50 years)	Negative
		-	Age (≥50 vs <50 years)	-
		-	Education	-
-		Employment	-	
-		Economic status	-	
-		Single versus married	-	
-		Performance status	-	
-		Score in the domains of SCNS – health system and information, care and support	-	
Overall well-being		Higher score in the domains of SCNS – psychological, physical and daily living	Negative	
-		Higher score in the domains of SCNS – sexuality	Positive	
Thanapan, 2015 ⁴⁶		Functional well-being	Better subjectively measured cosmesis	Negative
		-	Objectively measured cosmesis	-
		-	Self-rated breast symmetry	-
		Social well-being	Breast-conserving surgery versus mastectomy	Positive
	Overall well-being, physical well-being, emotional well-being and functional well-being	Satisfaction with treatment	Not specified	
	Chen, 2013 ⁴⁵	Emotional well-being	Older age (≥40 versus <40 years)	Positive
Overall well-being, physical well-being, emotional well-being and breast cancer subscale		Time since treatment (1, 2 and 5 years)	Positive	
Social well-being		Can read and write versus illiterate	Positive	
-		Employed versus unemployed	Positive	
Physical well-being, emotional well-being and breast cancer subscale		Higher stage	Negative	
-		Breast-conserving surgery versus mastectomy with reconstruction	-	
Chang, 2007 ⁴⁵	-	Chemotherapy (yes vs no)	-	
	-	Radiotherapy (yes vs no)	-	
	-	Hormone therapy (yes vs no)	-	
	-	-	-	
	-	-	-	
	-	-	-	

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Kim, 2013 ¹⁰⁰	Functional well-being	Oestrogen receptor status positive	Positive
So, 2013 ¹⁰¹	Social well-being and functional well-being Breast cancer subscale	Having social support	Positive Negative
Zou, 2014 ^{75,††}	Overall well-being	Higher optimism Affront coping mode versus give-in coping mode Appraisal of illness (higher scores indicate more stress) Having distress symptoms	Positive Negative
Jiao-Mei, 2015 ⁷⁴	-	Age (years)	-
-	-	Time since diagnosis (months)	-
-	-	Stage	-
Overall well-being, physical well-being, social well-being, emotional well-being and functional well-being		Post-traumatic growth (low, moderate and high)	Positive
Overall well-being and social well-being		Adverse childhood event (0, 1 and ≥2)	Negative
Qiu, 2016 ¹⁰²		BRCA 1/2 carriers versus non-carriers	-
Shin, 2017 ⁵⁷		Age (≤39, 40–49, 50–59 and ≥60)	-
Overall well-being		Education (middle school vs high school vs university)	Positive
-		Employment (yes vs no)	Positive
-		Marital status (single vs married)	-
-		Religion (yes vs no)	-
Overall well-being		Time since diagnosis (≤1, 1–5 and ≥5)	-
-		Recurrence (yes vs no)	Negative
-		Breast-conserving surgery versus mastectomy	-
Overall well-being		Breast-conserving surgery versus mastectomy with reconstruction	-
-		Empowerment	Positive
-		Self-help group (yes versus no)	-
So et al., 2011 ⁴⁵	Overall well-being, physical well-being, emotional well-being and breast cancer subscale	Age (≥60 vs <60 years)	Positive
Park, 2013 ⁵²		Age (≤39 vs 40–49 vs 50–59 years)††	-
Overall well-being		Household income (<2, 2–4, >4 million KRW/month)††	Positive
-		Stage (1, 2, 3/4, unknown)††	Negative
Overall well-being		Length of chemotherapy (<6, 6–12 and ≥12 months)††	-
-		Satisfaction with family support (unsatisfied, moderate and satisfied)††	Positive
-		Frequency of sexual activity (none within 6 months, ≤3 in 6 months, 2–3 per month and ≥1 per week)	-
Overall well-being, social well-being, emotional well-being, functional well-being and breast cancer subscale		Sexual function	Positive
Overall well-being, physical well-being, social well-being, emotional well-being, functional well-being and breast cancer subscale		Experienced menopausal symptoms	Negative

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes	
Pahlevan Sharif, 2017 ⁷⁶	Overall well-being, social well-being, functional well-being and breast cancer subscale	Higher external locus of control	Negative	
	Overall well-being and functional well-being	Higher internal locus of control	Positive	
Sharif, 2017 ⁷⁷	Overall well-being, social well-being, emotional well-being, functional well-being and breast cancer subscale	Higher score on powerful others	Negative	
	Overall well-being, social well-being and breast cancer subscale	Higher score on chance	Negative	
	Breast cancer subscale	Avoidant emotional coping	Negative	
	Overall well-being, social well-being and functional well-being	Active emotional coping	Positive	
	Social well-being and functional well-being	Problem focused coping	Positive	
So, 2009 ¹⁰³	-	-	-	
Pandey, 2005 ¹⁰⁴	-	-	-	
Longitudinal (n=3)	Emotional well-being and social well-being	Age (>60 vs ≤60 years)	Positive	
		Longer time since enrolment (for most comparison between 6/12/18/24-months vs time since enrolment)		
Cao, 2016 ¹⁰⁵		Mastectomy (yes vs no)	Negative	
		Prior chemotherapy (yes vs no)	Negative	
		Axillary lymph node dissection (yes vs no)	Negative	
Pandey, 2006 ⁸⁸	Emotional well-being and social well-being	Postsurgery versus presurgery	Negative	
Taira, 2012 ^{84,111}	Overall well-being, physical well-being, functional well-being and breast cancer subscale			
	-	Concomitant disease (compared at 6, 12 and 24 months)	-	
	-	Nodal involvement (compared at 6, 12 and 24 months)	-	
	-	Breast-conserving surgery versus mastectomy (compared at 6, 12 and 24 months)	-	
	-	Intercostobrachial nerve preservation (compared at 6, 12 and 24 months)	-	
	Overall well-being and breast cancer subscale	Chemotherapy (yes vs no) (compared at 6 months)	Negative	
	Breast cancer subscale	Chemotherapy (yes vs no) (compared at 12 and 24 months)	Negative	
	-	Hormone therapy (compared at 6, 12 and 24 months)	-	
	Study using both the EORTC-QLQ-C30 and FACT-G questionnaire			
	Cross-sectional (n=1)			

Continued

Table 3 Continued

First author, year of publication	QoL outcomes	Determinant	Type of association with QoL outcomes
Gong, 2017 ⁶⁹	Global health status, physical functioning, role functioning, emotional functioning, social functioning, overall well-being, physical well-being, social well-being, emotional well-being and functional well-being Nausea and vomiting, pain, dyspnoea and appetite loss Global health status, role functioning, cognitive functioning, emotional functioning, overall well-being, physical well-being and functional well-being Fatigue, nausea and vomiting, dyspnoea, appetite loss and diarrhoea Global health status, physical functioning, role functioning, cognitive functioning, emotional functioning, social functioning, overall well-being, social well-being and functional well-being Fatigue, nausea and vomiting, dyspnoea, appetite loss, constipation and financial difficulty Global health status, physical functioning, cognitive functioning, emotional functioning, overall well-being, physical well-being, social well-being, emotional well-being and functional well-being Dyspnoea, appetite loss and constipation Global health status, physical functioning, role functioning, cognitive functioning, emotional functioning, social functioning, overall well-being, physical well-being, social well-being, emotional well-being and functional well-being Fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation and financial difficulty	Exercisers versus non-exercisers Frequency of exercise among exercisers (<5 vs ≥5 times a week) Vegetable intake (≤250 vs >250 g/day) Daily fruit intake (yes vs no) Healthy behaviour (ref: 1 vs 0 vs 2 vs 3)	Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative

Positive association implies an increase in measured score based on the respective scoring manual of each questionnaire. Global health status and functioning status of EORTC-QLQ-C30/-BR23; positive association implies better quality of life and functioning. Symptoms scales of EORTC-QLQ-C30/EORTC-QLQ-BR23; positive association implies higher level of symptoms. All scales of FACT-G/-B; positive association implies better well-being

*Domains studied: global health status, physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning.

†Domains studied: global health status.

‡Domains studied: overall well-being.

§Apart from determinant 'treatment status', domain studied: global health status.

¶Domains studied: global health status and body image.

**Domains studied: global health status, physical functioning, role functioning, emotional functioning, social functioning, body image, sexual functioning, sexual enjoyment and future perspective.

††Domains studied: global health status, physical functioning, role functioning, emotional functioning, social functioning, body image, breast symptoms and arm symptoms.

‡‡Domains studied: overall well-being, physical well-being, social well-being, functional well-being.

§§Significance not mentioned (JT Chang).

¶¶Domains studied: overall well-being and breast cancer subscale.

MBP: mind-body practices; NP: natural products; NRCMS, New Rural Cooperative Medical Scheme health insurance; SCNS, the short-form Supportive Care Needs Survey questionnaire; TMed, traditional medicine; UEBMI, Urban Employee Basic Medical Insurance; URBMI, Urban Resident Basic Medical Insurance.

Supportive Care Needs Survey (SCNS) also reported conflicting results. Table 4 presents a summary of determinants which were found to be associated with global health status and/or overall well-being.

Age

Park *et al* found that patients with breast cancer who were of older age had poorer overall well-being and that older age was associated with longer time since surgery.⁴² In patients who were at least 5-year postdiagnosis, older age was associated with poorer overall well-being in those.^{43 44} In patients undergoing chemotherapy or radiotherapy, So *et al* observed that older age was associated with better overall well-being than those aged below 60 years.⁴⁵ Apart from the study by So *et al*,⁴⁵ other studies^{21 46–48} on this association showed that older age was associated with poorer global health status.

Marital status

Chui *et al*²¹ and Edib *et al*⁴⁸ found that women who were single (as compared with ever married) and unmarried (as compared with currently married and widowed/divorced), respectively, had better global health status. However, Chang *et al* found that being married as compared with being single/divorced/widowed was associated with better global health status.⁴⁹ The classification of widowed/divorced, which confers poorer HRQL than married, may have contributed to the difference in findings of Chui *et al*²¹ and Chang *et al*,⁴⁹ in addition the proportion of women who were never married (single) is small in both populations (11% unmarried and 17% unmarried/divorced/widowed, respectively).

Income

Edib *et al*⁴⁸ and Huang *et al*⁵⁰ found that higher household income was associated with better global health status, while Chui *et al*²¹ found the opposite. While some reported higher household income to be also associated with better overall well-being, others did not find evidence of associations.^{44 51} Standard of living for the population is different among the different studies, making it difficult to access if the association seen was a result of the choice of categorisation of household income. Among the six studies^{21 43 48–50 52} that assessed household income, Chui *et al* were the only ones who looked at the effect of household income during treatment, in particular during chemotherapy, and found that higher income was associated with poorer global health status.²¹ Lower income might have been less of a concern in Malaysia, where lower income patients have access to welfare assistance, while patients of higher income are not eligible for. In addition, Edib *et al* studied survivors in the post-treatment period in Malaysia and found that higher household income was associated with better global health status.⁴⁸

Other demographic determinants

Shorter time since breast cancer diagnosis,^{39 41 46–48 50} being of Chinese or Indian ethnicity as compared with Malay ethnicity,^{21 48 53} lower educational level^{21 49} and

being diagnosed at later calendar year⁵⁴ were associated with poorer global health status. Shorter time since diagnosis of breast cancer^{43 55 56} and lower educational level^{43 57} were associated with poorer overall well-being.

Tumour characteristics

Advanced stage disease was associated with poorer global health status^{46 48 50 58} and poorer overall well-being.⁵²

Type of surgery

Edib *et al* observed that women who underwent breast-conserving surgery had better global health status than women who had mastectomy.⁴⁸ However, Dubashi *et al*⁵⁹ and Huang *et al*⁶⁰ found that patients who had breast-conserving surgery had poorer global health status than those who had mastectomy. This could be due to the higher levels of, pain, breast symptoms and arm symptoms experienced by patients who had breast-conserving surgery as compared with those who had mastectomy.^{59 60} Furthermore, other studies comparing breast-conserving surgery and mastectomy did not find associations with global health status^{46 47 61 62} or overall well-being.^{43 44 55 57 63 64}

Radiotherapy

Kao *et al*⁴⁶ and Shi *et al*⁴⁷ found that at 2 years postdiagnosis, women who have had radiotherapy had better global health status as compared with those who did not receive radiotherapy; however, Edib *et al*⁴⁸ found contrary results. After adjusting for potential confounders, the association between radiotherapy with poorer global health status was no longer significant.⁴⁸ Park *et al*⁵⁸ and Hong-Li *et al*⁵⁵ did not find association between having had radiotherapy and global health status or overall well-being.

Hormone therapy

Edib *et al*⁴⁸ found hormone therapy was associated with poorer global health status; however, Kao *et al*⁴⁶ and Shi *et al*⁴⁷ found the opposite. Kao *et al*⁴⁶ and Shi *et al*⁴⁷ obtained information on hormone therapy from medical records. Using the classification of ever or current user of hormone therapy may result in misclassifying those who had discontinued with those on active therapy. Furthermore, patients who suffer adverse events, like hot flashes, are more likely to discontinue hormone therapy, which may result in patients who are on hormone therapy to be incorrectly perceived as having better global health status.^{65 66} In other studies, hormone therapy was not associated with global health status⁵⁸ or overall well-being.^{44 55 64}

Other treatment determinants

Ongoing treatment (vs completed treatment),⁶⁷ having received chemotherapy^{46 48} or not having delayed chemotherapy^{21 39} were associated with poorer global health status. Recent (≤ 30 days) postsurgery (vs presurgery)⁶⁸ and having received chemotherapy^{43 64} were associated with poorer overall well-being.

Table 4 Determinants associated with global health status and/or overall well-being

Determinants studied	Better global health status (GHS)/overall well-being (OWB)	Poorer GHS/OWB	Others
Demographic			
Time since diagnosis/surgery/ treatment/enrolment: GHS – CS: refs 48, 50 and 67 OWB – L: ref 46 GHS – L: refs 41, 46, 47 and 78 OWB – CS: refs 43, 44, 51, 55, 74 and 95 OWB – L: refs 56 and 105	Longer time since diagnosis: GHS – CS: refs 39, 47, 48 and 50 OWB – L: ref 46 12 months versus at time of diagnosis: GHS – L: ref 41 Longer time since treatment: OWB – CS: ref 55	–	Time since diagnosis (<11.9 months) < (≥24 months) < (12–23.9 months): OWB – CS: ref 43
Ethnicity: GHS – CS: refs 21, 48 and 53	–	–	Malay<Chinese<Indian: GHS – CS: ref 48 Malay>Indian GHS – CS: ref 21 Chinese>Indian GHS – CS: ref 21
Education: GHS – CS: refs 21 and 49 OWB – CS: refs 43, 44, 51, 55, 71 and 95	(Higher) Education: GHS – CS: refs 21 and 49 OWB – CS: ref 95	–	Primary school or less<middle/high school<college or more: OWB – CS: ref 43
Year of diagnosis: GHS – CS: ref 54	–	Year of diagnosis: GHS – CS: ref 54	–
Older age: GHS – CS: refs 21, 48, 58 and 60 GHS – L: refs 46 and 47 OWB – CS: refs 42–45, 51, 52, 55, 71, 74 and 95 OWB – L: ref 105	–	Older age: GHS – CS: ref 48 GHS – L: refs 46 and 47 OWB – CS: refs 42–45	–
Employment: GHS – CS: refs 48 and 49 OWB – CS: refs 43, 44, 51, 55, 71 and 95	Employed (yes): OWB – CS: ref 95	–	Employed>retired>housewife: GHS – CS: ref 48 Working in public sector>private sector>farmers/unemployed: OWB – CS: ref 43
Income: GHS – CS: refs 21 and 48–50 OWB – CS: refs 43 and 52	(Higher) Income: GHS – CS: ref 21	–	–
Marital status: GHS – CS: refs 21, 48, 49 and 60 OWB – CS: refs 43, 44, 51, 71 and 95	–	–	Widowed/divorced<married<unmarried GHS – CS: ref 48 Single<married GHS – CS: ref 21 Married<single/ divorced/separated/widowed: GHS – CS: ref 49
Religion: GHS – CS: ref 67 GHS – L: ref 92 OWB – CS: ref 95	Presence of religion: GHS – CS: ref 67 Higher intrinsic religiosity at 1 year post-surgery GHS – L: ref 92	–	–
Comorbidity: GHS – CS: refs 50, 67 and 73 GHS – L: ref 46 OWB – CS: refs 44 and 51 OWB – L: ref 64	–	Comorbidity (yes): GHS – CS: refs 50 and 67 Diabetes mellitus (yes): GHS – CS: ref 73 (Higher) Charlson comorbidity index: GHS – L: ref 46	GHS – CS: Type 1 <no diabetes mellitus: GHS – CS: ref 73 Type 2 <no diabetes mellitus: GHS – CS: ref 73
Clinical			
Tumour stage: GHS – CS: refs 21, 48–50 and 58 GHS – L: ref 46 OWB – CS: refs 43, 51, 52, 55 and 74	–	(Higher) stage: GHS – CS: refs 48 and 50: OWB – CS: ref 52 Metastatic disease: GHS – CS: ref 58 Stage 3/4 versus 0/1: GHS – L: ref 46	–
Recurrence: GHS – CS: ref 50 OWB – CS: ref 95	–	Recurrence (yes): OWB – CS: ref 95	–
Treatment			

Continued

Table 4 Continued

Determinants studied	Better: global health status (GHS)/overall well-being (OWB)	Poorer GHS/OWB	Others
(Type of surgery) BCS versus TM: GHS – CS: refs 48, 49 and 59–61 GHS – L: refs 38, 46 and 47 OWB – CS: refs 43, 44 and 63 OWB – L: ref 64 BCS versus mastectomy with reconstruction (TM+R): GHS – CS: refs 47 and 61 OWB – CS: ref 95 BCS versus TM versus TM+R GHS – CS: ref 62 OWB – CS: ref 55 TM (yes): OWB – L: ref 105	-	-	BCS>TM: GHS – CS: refs 48, 59 and 60
Chemotherapy GHS – CS: refs 21, 48 and 58 GHS – L: refs 37, 40, 46 and 47 OWB – CS: refs 43, 44, 52 and 55 OWB – L: refs 64 and 105	-	Chemotherapy (yes): GHS – CS: ref 48 GHS – L: refs 46 and 47 OWB – CS: ref 43	Chemotherapy on schedule=positioned: GHS – CS: ref 21 At cycle 1-3>6: GHS – L: ref 40 Chemotherapy (yes)<no (compared at 6 months) OWB – L: ref 64
Radiotherapy: GHS – CS: refs 48, 58 and 96 GHS – L: refs 46, 47 and 97 OWB – CS: ref 55	Radiotherapy (yes): GHS – L: refs 46 and 47	Radiotherapy (yes): GHS – CS: ref 48	-
Hormone therapy: GHS – CS: refs 48 and 58 GHS – L: refs 46 and 47 OWB – CS: refs 44, 51 and 55 OWB – L: ref 64	Hormone therapy (yes): GHS – L: refs 46 and 47 OWB – CS: ref 51	Hormone therapy (yes) GHS – CS: ref 48	-
Immune therapy: GHS – CS: ref 48	Immune therapy (yes): GHS – CS: ref 48	-	-
Treatment combination: (surgery (S), chemotherapy (C), radiotherapy (R), hormone therapy (H), targeted therapy (T)): GHS – CS: ref 50	-	-	C>S+C+H > S+C+R+H+T>S+C>others>S+R+hour>S+C+R+hour>S+C+R
Treatment status: GHS – CS: refs 49 and 67	-	Treatment status (incomplete): GHS – CS: ref 67	Post-treatment=ongoing treatment=non-treatment: GHS – CS: ref 67
Lifestyle			
Exercise: GHS – CS: refs 69 and 95 OWB – CS: ref 69	Exercise (yes): GHS and OWB – CS: ref 69 (Higher) Frequency of exercise: GHS and OWB – CS: ref 69	-	-
Diet: GHS and OWB – CS: ref 69	(Higher) Vegetable intake: GHS and OWB – CS: ref 69 Daily fruit intake (yes): GHS and OWB – CS: ref 69	-	-
Healthy behaviour: GHS and OWB – CS: ref 69	(More) Healthy behaviour: GHS and OWB – CS: ref 69	-	-
Unmet needs			
Short-form Supportive Care Needs Survey (SCNS) – psychological, physical and daily living, self-rated health system and information, care and support: GHS – CS: refs 48, 69 and 70 OWB – CS: refs 51 and 71	(Higher) Scores for sexuality: OWB – CS: ref 71	(Higher) Scores in all domains: GHS – CS: ref 70 OWB – CS: ref 51 (Higher) Scores for psychological, physical and daily living: GHS – CS: ref 48 OWB – CS: ref 71 (Higher) Scores for care and support: GHS – CS: ref 48	-
Others			
Complementary and complementary medicine: GHS – CS: refs 21, 22 and 58 OWB – CS: ref 43	Traditional Chinese medication (yes): OWB – CS: ref 43	-	-
Cosmetic appearance: GHS – CS: ref 61 OWB – CS: ref 98	(Better) Subjectively measured cosmetic appearance: GHS – CS: ref 61	-	-

Continued

Table 4 Continued

Determinants studied	Better global health status (GHS)/overall well-being (OWB)	Poorer GHS/OWB	Others
Symptom distress: GHS – CS: ref 54 OWB – CS: ref 75	–	Symptom distress: GHS – CS: ref 54 OWB – CS: ref 75	–
Involvement in decision making: GHS – CS: refs 67 and 72	Involvement in decision making (yes): GHS – CS: refs 67 and 72	–	–
Reflection of own value to decision: GHS – CS: ref 72	Reflection of own value to decision (yes): GHS – CS: ref 72	–	–
Problem obtaining surgery: GHS – CS: ref 72	–	Problem obtaining surgery (yes): GHS – CS: ref 72	–
Problems before surgery: GHS – CS: ref 67	–	Problems before surgery (yes): GHS – CS: ref 67	–
Experience of treatment toxicity: GHS – CS: ref 72	–	Experience of treatment toxicity (yes): GHS – CS: ref 72	–
Hospitalisation with treatment toxicity: GHS – CS: ref 72	–	Hospitalisation with treatment toxicity (yes): GHS – CS: ref 72	–
Time needed to travel from home to hospital: OWB – CS: ref 51	–	(Longer) Time needed to travel from home to hospital: OWB – CS: ref 51	–
Perceived overall medical care: GHS – CS: ref 67	(Better) Perceived overall medical care: GHS – CS: ref 67	–	–
Preoperative quality of life score: GHS – L: ref 47	(Higher) Preoperative quality of life score: GHS – L: ref 47	–	–
Sexual activity/function: OWB – CS: ref 52	(Higher) Frequency of sexual activity: OWB – CS: ref 52 (Higher) Sexual function: OWB – CS: ref 52	–	–
Experiencing menopausal symptoms: OWB – CS: ref 52	–	Experiencing menopausal symptoms: OWB – CS: ref 52	–
Symptom management self-efficacy: GHS – CS: ref 34	Symptom management self-efficacy: GHS – CS: ref 34	–	–
Insurance: OWB – CS: ref 43	–	–	UIBM/AFPCMS<UEBMI health insurance<undefined: OWB – CS: ref 43
Optimism: OWB – CS: ref 75	(Higher) Optimism: OWB – CS: ref 75	–	–
Positive mood: OWB – L: ref 56	Positive mood: OWB – L: ref 56	–	–
Boredom: OWB – L: ref 56	–	(Higher) Levels of boredom: OWB – L: ref 56	–
Appraisal of illness: OWB – CS: ref 75	–	(Higher) Scores for appraisal of illness (ie, more stress): OWB – CS: ref 75	–
Post-traumatic growth: OWB – CS: ref 74	(Higher) Post-traumatic growth: OWB – CS: ref 74	–	–
Adverse childhood event: OWB – CS: ref 74	–	More adverse childhood event: OWB – CS: ref 74	–
Locus of control: OWB – CS: ref 76	(Higher) Internal locus of control: OWB – CS: ref 76	(Higher) External locus of control: OWB – CS: ref 76 (Higher) Score on powerful others: OWB – CS: ref 77 (Higher) Score on chance: OWB – CS: ref 77	–
Coping mode: OWB – CS: refs 75 and 77	Active emotional coping: OWB – CS: ref 77	–	Affront coping mode>give in coping mode: OWB – CS: ref 75
Empowerment: OWB – CS: ref 95	Empowerment (yes): OWB – CS: ref 95	–	–
Family harmony status: OWB – CS: ref 43	(Good) family harmony status: OWB – CS: ref 43	–	–

Continued

Table 4 Continued

Determinants studied	Better global health status (GHS)/overall well-being (OWB)	Poorer GHS/OWB	Others
Interaction with friends/neighbours: OWB – CS: ref 43	Interaction with friends/neighbours: OWB – CS: ref 43	-	-
Participation in healing club: OWB – CS: ref 43	Participation in healing club: OWB – CS: ref 43	-	-
Participation in peer-patient activities and communication: OWB – CS: ref 43;	Participation in peer-patient activities and communication: OWB – CS: ref 43	-	-
Social support: OWB – CS: refs 43 and 101	(Higher) Score on Perceived Social Support Scale: OWB – CS: ref 43	-	-
Satisfaction with family support: OWB – CS: ref 52	Satisfaction with family support: OWB – CS: ref 52	-	-

BCS, breast-conserving surgery; CS, cross-sectional study; L, longitudinal study; NRCMS, New Rural Cooperative Medical Scheme health insurance; TM, mastectomy; UEBMI, Urban Employee Basic Medical Insurance; URBMI, Urban Resident Basic Medical Insurance.

Complementary and alternative medication

The use of complementary and alternative medication in general, including dietary supplements, prayer, exercise and/or self-help techniques, was not associated with overall well-being.^{21 22} However, the use of traditional Chinese medication,⁴³ empowerment of patients with breast cancer⁵⁷ and participating in self-help groups⁵⁷ were independently associated with better overall well-being.

Lifestyle

Gong *et al* found that patients who had less healthy behaviour (comparing zero healthy behaviour, 2, or 3 to 1) had lower global health status and overall well-being.⁶⁹ Patients with breast cancer who did not exercise (vs exercise) or with lower frequency of exercising (vs ≥ 5 times a week) had lower global health status and overall well-being.⁶⁹ Furthermore, those who had low vegetable (vs >250 g per day) intake and did not eat fruits daily had lower global health status and overall well-being.⁶⁹

Unmet needs

Having more unmet needs, especially in the physical and daily living, were associated with poorer global health status^{48 70} and poorer overall well-being.^{44 51} So *et al*⁵¹ found that women who had unmet sexuality needs (measured by SCNS) had poorer overall well-being, while Park *et al*⁷¹ reported the opposite. Park *et al* found that higher needs was associated with better overall well-being in 52 women who experienced recurrence of breast cancer, citing that patients who have better sexual functioning are more likely to have more sexuality needs.⁷¹ Akechi *et al*⁷⁰ found that unmet sexuality need was associated with poorer global health status, while Edib *et al*⁴⁸ did not find such association.

Others

Lack of involvement in decision making,^{67 72} lower self-efficacy in symptom management,⁵⁴ poorer perceived overall medical care⁶⁷ and having higher Charlson comorbidity index or comorbidities, including diabetes, hypertension and arthritis,^{46 50 73} were associated with poorer global health status. Adopting a give-in coping mode or believing that they are not in control,^{74–77} lower perceived social support and lower self-efficiency^{43 52 57} and poorer perceived overall medical care⁴³ were associated with poorer overall well-being.

Differences in quality of life between patients with breast cancer patients and general population

Two studies both conducted in Korea studied differences in global health status between patients with breast cancer and the general population.^{67 78} Lee *et al* found that global health status was not different among patients who had completed treatment for recurrent breast cancer as compared with the general population.⁶⁷ However, role functioning, cognitive functioning and social functioning were lower, and fatigue levels and financial difficulties were higher in patients treated for

recurrence as compared with the general population.⁶⁷ Lee *et al* compared patients with breast cancer to the general population at two time points, immediately after diagnosis and 1 year after diagnosis and found that the general population had higher global health status at both time points.⁷⁸

DISCUSSION

In Asia, patients with breast cancer have poorer HRQL than the general population. Patients with comorbidities, with chemotherapy, lower social support and with more unmet needs have poorer quality of life. However, HRQL improves with time since diagnosis and having healthier behaviour is associated with better HRQL. Within and across the scope of each questionnaire, most associations with poor global health status or overall well-being were concordant. Discordant results in studies were found in the associations of age, marital status, household income, type of surgery, radiotherapy and hormone therapy, and unmet sexuality needs with global health status or overall well-being.

Patients with one or more comorbidities during the time of survey had poorer HRQL. Comorbidity occurs in 20%–30% of patients with breast cancer.⁷⁹ Comorbidities may be pre-existence or developed after diagnosis; hypertension, arthritis and diabetes are common to patients with breast cancer.¹⁴ Studies outside Asia showed similar results; having less co-morbidity was also found to be associated with better HRQL in African-American and Latina breast cancer survivors.^{80 81} Having pre-existing diabetes was associated with poorer HRQL, in patients with early breast cancer in the USA.⁸² In addition, patients with pre-existing comorbidities are more likely to have treatment complications, which may lead to poorer HRQL.⁷⁹

In Asian patients with breast cancer, of all treatments studied, only being on or received chemotherapy was clearly associated with poorer HRQL. This is in agreement with Wöckel *et al*, who found that patients who received chemotherapy had decreased HRQL, and it was more likely to remain low.⁸³ However, patients on chemotherapy are more likely to be diagnosed with advanced stage disease which was also found to be associated with HRQL. Other treatments, like surgery, are less likely to be associated with advanced stage disease, and may be the reason for the null findings. Furthermore, patients with poorer prognosis or who are undergoing chemotherapy are more likely to experience pain, fatigue and potentially other adverse events.^{84 85}

The lack of social support and higher unmet needs were associated with poorer HRQL, in Asian countries. Having a large percentage of unmet needs is not unique to Asia.^{86 87} Provision of social support should be in-line with the needs of the patient, so as to not adversely impact their HRQL.^{88 89} In this review, social support, in areas that enable patients to be empowered with higher self-efficacy, was associated with better HRQL. The provision for the educational needs or having access to the service of a

breast care nurse may help in reducing unmet needs and provide social support from an institutional effort.^{89 90}

We acknowledge that this systematic review has some limitation. The studies included had varying patient selection criteria, which may be the reason for discordance results in certain determinants. Studies conducted in patients during the treatment period would differ from those conducted after completion of treatment. The choice of statistical analysis varies, with most reporting associations from linear models and some from correlation analysis; thus, we were not able to provide a sense of the level of association. Non-standard methods of measuring determinants were used in some studies, limiting the comparability of the studies. Furthermore, we cannot determine the direction of association from cross-sectional studies; it is possible that some determinant, such as unmet needs and use of CAM, were the result of poorer HRQL. While most of the studies of longitudinal design were of high quality, the majority of the cross-sectional design studies were of moderate or poor quality. Future cross-sectional studies should consider reporting reasons for non-response and include multiple sites if sample size is insufficient.

CONCLUSION

Patients with breast cancer in Asia have a poorer HRQL than the general population. A shorter time since diagnosis of breast cancer,^{39 41 43 46–48 50 55 56} having a Chinese or Indian ethnic background as compared with Malay ethnicity,^{21 48 53} lower educational level^{21 43 49 57} and advanced stage breast cancer disease^{46 48 50 52 58} were associated with poorer HRQL. There is some evidence that patients with comorbidities or with chemotherapy are more likely to experience poorer HRQL. The lack of social support and having unmet needs may predict poorer HRQL. Further studies into methods to provide social support in the Asian setting is needed to identify effective ways to improve patients' HRQL.

Contributors H MV, P J H and S A M G designed the study. P J H and S A M G performed the systematic review. P J H wrote the manuscript. All authors discussed and revised the manuscript.

Funding The study was carried out with the support from the National University Hospital, Singapore, Clinician Scientist Award, National Medical Research Council R-608-000-093-511 and Asian Breast Cancer Research Fund N-176-000-023-091 awarded to M H.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No dataset was used in this systematic review.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Youlden DR, Cramb SM, Yip CH, *et al.* Incidence and mortality of female breast cancer in the Asia-Pacific region. *Cancer Biol Med* 2014;11:101–15.
2. Agarwal G, Pradeep PV, Aggarwal V, *et al.* Spectrum of breast cancer in Asian women. *World J Surg* 2007;31:1031–40.
3. Mousavi-Jarrahi SH, Kasaean A, Mansori K, *et al.* Addressing the younger age at onset in breast cancer patients in Asia: an age-period-cohort analysis of fifty years of quality data from the international agency for research on cancer. *ISRN Oncol* 2013;2013:1–8.
4. Kim Z, Min SY, Yoon CS, *et al.* The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database. *J Breast Cancer* 2015;18:103–11.
5. Keramatina A, Mousavi-Jarrahi SH, Hiteh M, *et al.* Trends in incidence of breast cancer among women under 40 in Asia. *Asian Pac J Cancer Prev* 2014;15:1387–90.
6. Sung H, Rosenberg PS, Chen WQ, *et al.* Female breast cancer incidence among Asian and Western populations: more similar than expected. *J Natl Cancer Inst* 2015;107.
7. Virani S, Sriplung H, Rozek LS, *et al.* Escalating burden of breast cancer in southern Thailand: Analysis of 1990–2010 incidence and prediction of future trends. *Cancer Epidemiol* 2014;38:235–43.
8. Allemani C, Weir HK, Carreira H, *et al.* CONCORD Working Group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015;385:977–1010.
9. Moon EK, Park HJ, Oh CM, *et al.* Cancer incidence and survival among adolescents and young adults in Korea. *PLoS One* 2014;9:e96088.
10. Zhu J, Chen JG, Chen YS, *et al.* Female breast cancer survival in Qidong, China, 1972–2011: a population-based study. *BMC Cancer* 2014;14:318.
11. Ahn SG, Lee HM, Lee SA, *et al.* Long-term survival analysis of Korean breast cancer patients at a single center: improving outcome over time. *Yonsei Med J* 2014;55:1187–95.
12. Cella DF. Quality of life: concepts and definition. *J Pain Symptom Manage* 1994;9:186–92.
13. Teo I, Reece GP, Christie IC, *et al.* Body image and quality of life of breast cancer patients: influence of timing and stage of breast reconstruction. *Psychooncology* 2016;25.
14. Fu MR, Axelrod D, Guth AA, *et al.* Comorbidities and Quality of Life among Breast Cancer Survivors: A Prospective Study. *J Pers Med* 2015;5:229–42.
15. Jones SM, LaCroix AZ, Li W, *et al.* Depression and quality of life before and after breast cancer diagnosis in older women from the Women's Health Initiative. *J Cancer Surviv* 2015;9:620–9.
16. Dialla PO, Chu W-O, Roignot P, *et al.* Impact of age-related socioeconomic and clinical determinants of quality of life among long-term breast cancer survivors. *Maturitas* 2015;81:362–70.
17. Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. *J Pain* 2011;12:725–46.
18. Schoormans D, Czene K, Hall P, *et al.* The impact of co-morbidity on health-related quality of life in breast cancer survivors and controls. *Acta Oncol* 2015;54:727–34.
19. Gold M, Dunn LB, Phoenix B, *et al.* Co-occurrence of anxiety and depressive symptoms following breast cancer surgery and its impact on quality of life. *Eur J Oncol Nurs* 2016;20.
20. Kool M, Fontein DB, Meershoek-Klein Kranenbarg E, *et al.* Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients. *Breast* 2015;24:224–9.
21. Chui PL, Abdullah KL, Wong LP, *et al.* Quality of Life in CAM and Non-CAM Users among Breast Cancer Patients during Chemotherapy in Malaysia. *PLoS One* 2015;10:e0139952.
22. Kang E, Yang EJ, Kim SM, *et al.* Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: a descriptive study. *Support Care Cancer* 2012;20:461–73.
23. Ando M, Yonemori K, Katsumata N, *et al.* Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. *Cancer Chemother Pharmacol* 2012;69:457–65.
24. Nyman DW, Campbell KJ, Hersh E, *et al.* Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. *J Clin Oncol* 2005;23:7785–93.
25. Parsa P, Kandiah M, Abdul Rahman H, *et al.* Barriers for breast cancer screening among Asian women: a mini literature review. *Asian Pac J Cancer Prev* 2006;7:509–14.
26. Chin FW, Chan SC, Abdul Rahman S, *et al.* CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients. *Breast J* 2016;22:54–62.
27. Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
28. Chie WC, Chang KJ, Huang CS, *et al.* Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. *Psychooncology* 2003;12:729–35.
29. Luo N, Fones CS, Lim SE, *et al.* The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore. *Qual Life Res* 2005;14:1181–6.
30. Yun YH, Bae SH, Kang IO, *et al.* Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). *Support Care Cancer* 2004;12:441–5.
31. Yun YH, Park YS, Lee ES, *et al.* Validation of the Korean version of the EORTC QLQ-C30. *Qual Life Res* 2004;13:863–8.
32. Yoo HJ, Ahn SH, Eremenco S, *et al.* Korean translation and validation of the functional assessment of cancer therapy-breast (FACT-B) scale version 4. *Qual Life Res* 2005;14:1627–32.
33. Pandey M, Thomas BC, Ramdas K, *et al.* Quality of life in breast cancer patients: validation of a FACT-B Malayalam version. *Qual Life Res* 2002;11:87–90.
34. Wan C, Zhang D, Yang Z, *et al.* Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. *Breast Cancer Res Treat* 2007;106:413–8.
35. Loney PL, Chambers LW, Bennett KJ, *et al.* Critical appraisal of the health research literature: prevalence or incidence of a health problem. *Chronic Dis Can* 1998;19:170–6.
36. Wells GA SB, O'Connell D, Peterson J, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
37. Damodar G, Smitha T, Gopinath S, *et al.* Assessment of quality of life in breast cancer patients at a tertiary care hospital. *Arch Pharm Pract* 2013;4:15–20.
38. Munshi A, Dutta D, Kakkar S, *et al.* Comparison of early quality of life in patients treated with radiotherapy following mastectomy or breast conservation therapy: a prospective study. *Radiother Oncol* 2010;97:288–93.
39. Wani SQ, Khan T, Teeli AM, *et al.* Ashfaq-ul-Hassan. Quality of life assessment in survivors of breast cancer. *J Cancer Res Ther* 2012;8:272–6.
40. Sultan A, Choudhary V, Parganiha A. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles. *Chronobiol Int* 2017;34:609–23.
41. Ng CG, Mohamed S, See MH, *et al.* MyBCC Study group. Anxiety, depression, perceived social support and quality of life in Malaysian breast cancer patients: a 1-year prospective study. *Health Qual Life Outcomes* 2015;13:205.
42. Park BW, Lee S, Lee AR, *et al.* Quality of life differences between younger and older breast cancer patients. *J Breast Cancer* 2011;14:112–8.
43. Yan B, Yang LM, Hao LP, *et al.* Determinants of Quality of Life for Breast Cancer Patients in Shanghai, China. *PLoS One* 2016;11:e0153714.
44. Ohsumi S, Shimozuma K, Morita S, *et al.* Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. *Jpn J Clin Oncol* 2009;39:491–6.
45. So WK, Choi KC, Chan CW, *et al.* Age-related differences in the quality of life of Chinese women undergoing adjuvant therapy for breast cancer. *Res Gerontol Nurs* 2011;4:19–26.
46. Kao HY, Wu WH, Liang TY, *et al.* Cloud-Based Service Information System for Evaluating Quality of Life after Breast Cancer Surgery. *PLoS One* 2015;10:e0139252.
47. Shi HY, Uen YH, Yen LC, *et al.* Two-year quality of life after breast cancer surgery: a comparison of three surgical procedures. *Eur J Surg Oncol* 2011;37:695–702.
48. Edib Z, Kumarasamy V, Binti Abdullah N, *et al.* Most prevalent unmet supportive care needs and quality of life of breast cancer patients in a tertiary hospital in Malaysia. *Health Qual Life Outcomes* 2016;14:26.

49. Chang O, Choi EK, Kim IR, *et al.* Association between socioeconomic status and altered appearance distress, body image, and quality of life among breast cancer patients. *Asian Pac J Cancer Prev* 2014;15:8607–12.
50. Huang HY, Tsai WC, Chou WY, *et al.* Quality of life of breast and cervical cancer survivors. *BMC Womens Health* 2017;17:30.
51. So WK, Chow KM, Chan HY, *et al.* Quality of life and most prevalent unmet needs of Chinese breast cancer survivors at one year after cancer treatment. *Eur J Oncol Nurs* 2014;18:323–8.
52. Park H, Yoon HG. Menopausal symptoms, sexual function, depression, and quality of life in Korean patients with breast cancer receiving chemotherapy. *Support Care Cancer* 2013;21:2499–507.
53. Yusuf A, Ahmad Z, Keng SL, *et al.* Quality of life in Malay and Chinese women newly diagnosed with breast cancer in Kelantan, Malaysia. *Asian Pac J Cancer Prev* 2013;14:435–40.
54. Liang SY, Chao TC, Tseng LM, *et al.* Symptom-Management Self-efficacy Mediates the Effects of Symptom Distress on the Quality of Life Among Taiwanese Oncology Outpatients With Breast Cancer. *Cancer Nurs* 2016;39:67–73.
55. Hong-Li C, Xiao-Chun W, Jiang-Bin W, *et al.* Quality of life in patients with breast cancer and their rehabilitation needs. *Pak J Med Sci* 2014;30:126–30.
56. Wong WS, Fielding R. Change in quality of life in Chinese women with breast cancer: changes in psychological distress as a predictor. *Support Care Cancer* 2007;15:1223–30.
57. Shin S, Park H. Effect of empowerment on the quality of life of the survivors of breast cancer: The moderating effect of self-help group participation. *Jpn J Nurs Sci* 2017;14:311–9.
58. Park JE, Jang HJ, Seo KS. Quality of life, upper extremity function and the effect of lymphedema treatment in breast cancer related lymphedema patients. *Ann Rehabil Med* 2012;36:240–7.
59. Dubashi B, Vidhubala E, Cyriac S, *et al.* Quality of life among younger women with breast cancer: study from a tertiary cancer institute in south India. *Indian J Cancer* 2010;47:142–7.
60. Huang CC, Lien HH, Tu SH, *et al.* Quality of life in Taiwanese breast cancer survivors with breast-conserving therapy. *J Formos Med Assoc* 2010;109:493–502.
61. Kim MK, Kim T, Moon HG, *et al.* Effect of cosmetic outcome on quality of life after breast cancer surgery. *Eur J Surg Oncol* 2015;41:426–32.
62. Sun Y, Kim SW, Heo CY, *et al.* Comparison of quality of life based on surgical technique in patients with breast cancer. *Jpn J Clin Oncol* 2014;44:22–7.
63. He ZY, Tong Q, Wu SG, *et al.* A comparison of quality of life and satisfaction of women with early-stage breast cancer treated with breast conserving therapy vs. mastectomy in southern China. *Support Care Cancer* 2012;20:2441–9.
64. Taira N, Shimozuma K, Ohsumi S, *et al.* Abstract P4-14-07: Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life two years after breast cancer surgery. *Cancer Res* 2012;72:P4-14-07.
65. Hershman DL, Shao T, Kushi LH, *et al.* Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 2011;126:529–37.
66. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. *J Clin Oncol* 1995;13:2737–44.
67. Lee MK, Son BH, Hwang SY, *et al.* Factors affecting health-related quality of life in women with recurrent breast cancer in Korea. *Qual Life Res* 2007;16:559–69.
68. Pandey M, Thomas BC, Ramdas K, *et al.* Early effect of surgery on quality of life in women with operable breast cancer. *Jpn J Clin Oncol* 2006;36:468–72.
69. Gong XH, Wang JW, Li J, *et al.* Physical exercise, vegetable and fruit intake and health-related quality of life in Chinese breast cancer survivors: a cross-sectional study. *Qual Life Res* 2017;26:1541–50.
70. Akechi T, Okuyama T, Endo C, *et al.* Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. *Psychooncology* 2011;20:497–505.
71. Park BW, Hwang SY. Unmet Needs and Their Relationship with Quality of Life among Women with Recurrent Breast Cancer. *J Breast Cancer* 2012;15:454–61.
72. Noh DY, Nam SJ, Ahn SH, *et al.* Association of clinical experiences with patient-reported outcomes among breast cancer surgery patients: breast cancer quality care study. *Qual Life Res* 2008;17:215–25.
73. Tang Z, Wang J, Zhang H, *et al.* Associations between Diabetes and Quality of Life among Breast Cancer Survivors. *PLoS One* 2016;11:e0157791.
74. Jiao-Mei X, Wen G, Feng-Lin C. Quality of Life Among Breast Cancer Survivors 2 Years After Diagnosis: The Relationship With Adverse Childhood Events and Posttraumatic Growth. *Cancer Nurs* 2016;39:E32–9.
75. Zou Z, Hu J, McCoy TP. Quality of life among women with breast cancer living in Wuhan, China. *Int J Nurs Sci* 2014;1:79–88.
76. Pahlevan Sharif S. Locus of control, quality of life, anxiety, and depression among Malaysian breast cancer patients: The mediating role of uncertainty. *Eur J Oncol Nurs* 2017;27:28–35.
77. Sharif SP, Khanekharab J. External locus of control and quality of life among Malaysian breast cancer patients: The mediating role of coping strategies. *J Psychosoc Oncol* 2017;35:706–25.
78. Lee ES, Lee MK, Kim SH, *et al.* Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study. *Ann Surg* 2011;253:101–8.
79. Sogaard M, Thomsen RW, Bossen KS, *et al.* The impact of comorbidity on cancer survival: a review. *Clin Epidemiol* 2013;5(Suppl 1):3–29.
80. Miller AM, Ashing KT, Modeste NN, *et al.* Contextual factors influencing health-related quality of life in African American and Latina breast cancer survivors. *J Cancer Surviv* 2015;9:441–9.
81. Bloom JR, Stewart SL, Napoles AM, *et al.* Quality of life of Latina and Euro-American women with ductal carcinoma *in situ*. *Psychooncology* 2013;22:1008–16.
82. Jarvandi S, Pérez M, Schootman M, *et al.* Pre-Existing Diabetes in Early Stage Breast Cancer Patients is Associated with Lack of Improvement in Quality of Life 2 Years After Diagnosis. *Int J Behav Med* 2016;23:722–9.
83. Wöckel A, Schwentner L, Krockenberger M, *et al.* Predictors of the course of quality of life during therapy in women with primary breast cancer. *Qual Life Res* 2017;26:2201–8.
84. Hsu HT, Lin KC, Wu LM, *et al.* Symptom Cluster Trajectories During Chemotherapy in Breast Cancer Outpatients. *J Pain Symptom Manage* 2017;53:1017–25.
85. Hamer J, McDonald R, Zhang L, *et al.* Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. *Support Care Cancer* 2017;25:409–19.
86. Ellegaard MB, Grau C, Zachariae R, *et al.* Fear of cancer recurrence and unmet needs among breast cancer survivors in the first five years. A cross-sectional study. *Acta Oncol* 2017;56:314–20.
87. Hubbard G, Venning C, Walker A, *et al.* Supportive care needs of women with breast cancer in rural Scotland. *Support Care Cancer* 2015;23:1523–32.
88. Reynolds JS, Perrin NA. Mismatches in social support and psychosocial adjustment to breast cancer. *Health Psychol* 2004;23:425–30.
89. Helgeson VS, Cohen S, Schulz R, *et al.* Group support interventions for women with breast cancer: who benefits from what? *Health Psychol* 2000;19:107–14.
90. Ahern T, Gardner A, Courtney M. Exploring patient support by breast care nurses and geographical residence as moderators of the unmet needs and self-efficacy of Australian women with breast cancer: Results from a cross-sectional, nationwide survey. *Eur J Oncol Nurs* 2016;23:72–80.
91. Kim SH, Cho YU, Kim SJ, *et al.* Low bone density in breast cancer survivors in Korea: prevalence, risk factors and associations with health-related quality of life. *Eur J Oncol Nurs* 2013;17:S119.
92. Jang JE, Kim SW, Kim SY, *et al.* Religiosity, depression, and quality of life in Korean patients with breast cancer: a 1-year prospective longitudinal study. *Psychooncology* 2013;22:131.
93. Okamura M, Yamawaki S, Akechi T, *et al.* Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life. *Jpn J Clin Oncol* 2005;35:302–9.
94. Kang D, Kim IR, Choi EK, *et al.* Who are happy survivors? Physical, psychosocial, and spiritual factors associated with happiness of breast cancer survivors during the transition from cancer patient to survivor. *Psychooncology* 2017;26:1922–8.
95. Shin WK, Song S, Jung SY, *et al.* The association between physical activity and health-related quality of life among breast cancer survivors. *Health Qual Life Outcomes* 2017;15:132.
96. Sharma N, Purkayastha A. Impact of Radiotherapy on Psychological, Financial, and Sexual Aspects in Postmastectomy Carcinoma Breast Patients: A Prospective Study and Management. *Asia Pac J Oncol Nurs* 2017;4:69–76.
97. Munshi A, Dutta D, Budrukhar A, *et al.* Impact of adjuvant radiation therapy photon energy on quality of life after breast conservation therapy: linear accelerator versus the cobalt machine. *J Cancer Res Ther* 2012;8:361–6.

98. Thanarpan P, Somrit M, Rungarun J, *et al.* Cosmetic Outcomes and Quality of Life in Thai Women Post Breast Conserving Therapy for Breast Cancer. *Asian Pac J Cancer Prev* 2015;16:4685–90.
99. Chang JT, Chen CJ, Lin YC, *et al.* Health-related quality of life and patient satisfaction after treatment for breast cancer in northern Taiwan. *Int J Radiat Oncol Biol Phys* 2007;69:49–53.
100. Kim JH, Lee BJ, Bae JN, *et al.* Relationship of oestrogen receptor status to depressive symptoms and quality of life in breast cancer patients. *Acta Neuropsychiatr* 2013;25:283–8.
101. So WK, Leung DY, Ho SS, *et al.* Associations between social support, prevalent symptoms and health-related quality of life in Chinese women undergoing treatment for breast cancer: a cross-sectional study using structural equation modelling. *Eur J Oncol Nurs* 2013;17:442–8.
102. Qiu J, Guan J, Yang X, *et al.* Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing. *PLoS One* 2016;11:e0158531.
103. So WK, Marsh G, Ling WM, *et al.* The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. *Oncol Nurs Forum* 2009;36:E205–E214.
104. Pandey M, Thomas BC, SreeRekha P, *et al.* Quality of life determinants in women with breast cancer undergoing treatment with curative intent. *World J Surg Oncol* 2005;3:3.
105. Cao A, Zhang J, Liu X, *et al.* Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study. *Health Qual Life Outcomes* 2016;14:51.